Stock comparison
Harmony Biosciences Holdings
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 72B | LLY |
| Benjamin Graham | 60C | 86A | LLY |
| Philip Fisher | 75B | 86A | LLY |
| Peter Lynch | 62C | 74B | LLY |
| Joel Greenblatt | 28F | 78C | LLY |
| Charlie Munger | 62C | 85A | LLY |
| Terry Smith | 67B | 77C | LLY |
Side-by-side metrics
| Metric | HRMY | LLY |
|---|---|---|
| Market cap | $1.75B | $1T |
| P/E (TTM) | 11.8x | 36.6x |
| EV/EBIT | 6.4x | 34.1x |
| ROIC (TTM) | 12.5% | 32.06% |
| Gross margin | 76.55% | 83.51% |
| Net margin | 16.2% | 34.98% |
| Revenue CAGR 5y | 29.85% | 23.17% |
| EPS CAGR 5y | 46.45% | 40.81% |
| Debt / Equity | 0.2x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- Debt / Equity0.2xvs 1.4x+84%
- EV/EBIT6.4xvs 34.1x+81%
- P/E (TTM)11.8xvs 36.6x+68%
- Revenue CAGR 5y29.85%vs 23.17%+22%
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $1.75B+100%
- ROIC (TTM)32.06%vs 12.5%+61%
- Net margin34.98%vs 16.2%+54%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.